Apitope News

Latest Press Releases

Apitope to present at ECTRIMS 2019 Stockholm, Sweden

August 7, 2019

Professor David Wraith Apitope’s founder and CSO and Dr Lotta Jansson, Chief Research Officer are scheduled to attend ECTRIMS 2019. The conference is being held in Stockholm Sweden between 11th-13th September ECTRIMS 2019 at the Stockholmsmässan. Professor Wraith will present during Session 12 entitled ‘Immunopathogenesis and antigen specific therapies’ details of which are below: 13…

Details

Apitope Announces Publication of Data in International Peer-Reviewed Journal Thyroid on Graves’ disease Therapy

June 20, 2019

HASSELT, Belgium, and CHEPSTOW, UK, 20 June 19 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces publication of its clinical Graves’ disease data in Thyroid, one of the leading peer-reviewed thyroid disease related medical journals. The publication entitled: Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves’…

Details

Apitope Announces Management Changes

October 24, 2018

Keith Martin to retire as CEO, continue as Non-Executive DirectorHayley French appointed COO and interim CEO HASSELT, Belgium, and CHEPSTOW, UK, 24 October 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces that Chief Executive Officer (CEO) Dr Keith Martin has decided to retire from the…

Details

Apitope Announces Publication of Graves’ Disease Data in International Peer-Reviewed Journal, Endocrinology

August 14, 2018

HASSELT, Belgium, and CHEPSTOW, UK, 14 August 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces publication of its pre-clinical Graves’ disease data in Endocrinology, one of the leading peer-reviewed endocrinology medical journals. The publication entitled: Immunotherapy with apitopes® blocks the immune response to thyroid stimulating…

Details

Apitope announces positive results with novel treatment for Graves’ disease

April 16, 2018

Phase I data show early efficacy in the majority of patients and a very favourable safety profile HASSELT, Belgium, and CHEPSTOW, UK, 16 April 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases (including multiple sclerosis (MS), Graves’ disease and uveitis), today announced positive results from the Phase…

Details

Apitope Announces Publication of Data in International Peer-Reviewed Journal Neurology on Novel Multiple Sclerosis Therapy

March 19, 2018

HASSELT, Belgium, and CHEPSTOW, UK, 19 March 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announced publication of data on it multiple sclerosis treatment in Neurology, the official journal of the American Academy of Neurology and one of the world’s most widely read and highly cited…

Details